Search company, investor...

Founded Year

2011

Stage

IPO | IPO

Total Raised

$116.02M

Date of IPO

9/18/2020

Market Cap

0.15B

Stock Price

3.70

About Athira Pharma

Athira Pharma (NASDAQ: ATHA) operates as a drug development company. The company strives to improve human health by advancing new therapies for neurodegenerative diseases, like Alzheimer's and Parkinson's. The company's approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function. It was founded in 2011 and is based in Bothell, Washington.

Headquarters Location

18706 North Creek Parkway Suite 104

Bothell, Washington, 98011,

United States

(866) 725-0930

Loading...

Loading...

Athira Pharma Patents

Athira Pharma has filed 5 patents.

The 3 most popular patent topics include:

  • rare diseases
  • neurological disorders
  • psychiatric diagnosis
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/1/2017

6/1/2021

Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders

Grant

Application Date

6/1/2017

Grant Date

6/1/2021

Title

Related Topics

Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders

Status

Grant

Latest Athira Pharma News

Parkinson’s Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

Feb 20, 2024

Posted on DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2024” report provides comprehensive insights about 140+ Parkinson’s Disease companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Parkinson’s Disease Pipeline Report DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment. The leading Parkinson’s Disease companies working in the market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others. Promising Parkinson’s Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others. December 2023: AC Immune SA announced a study of Phase 2 clinical trials for ACI-7104.056 at Dose A. The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 vaccination in patients with early stages of Parkinson’s disease. This is a prospective, multicenter, placebo-controlled, double-blind, randomized study with adaptive features, comprising a screening period of up to 8 weeks, a 74-week double-blind treatment period, and a 26-week post-treatment follow-up period. December 2023: Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone and Sirolimus. A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL). July 2023: Hoffmann-La Roche announced a study of phase 2 clinical trials for Prasinezumab. This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson’s Disease (PD) who are on stable symptomatic PD medication. March 2023: Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson’s Disease with Motor Fluctuations. Request a sample and discover the recent advances in Parkinson’s Disease Treatment Drugs @  Parkinson’s Disease Pipeline Outlook Report In the Parkinson’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Parkinson’s Disease Overview Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Tavapadon: Cerevel Therapeutics Parkinson’s Disease Pipeline Therapeutics Assessment There are approx. 140+ key Parkinson’s Disease companies which are developing the Parkinson’s Disease therapies. The Parkinson’s Disease companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics. DelveInsight’s Parkinson’s Disease pipeline report covers around 150+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Coverage- Global Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others. Parkinson’s Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.

Athira Pharma Frequently Asked Questions (FAQ)

  • When was Athira Pharma founded?

    Athira Pharma was founded in 2011.

  • Where is Athira Pharma's headquarters?

    Athira Pharma's headquarters is located at 18706 North Creek Parkway, Bothell.

  • What is Athira Pharma's latest funding round?

    Athira Pharma's latest funding round is IPO.

  • How much did Athira Pharma raise?

    Athira Pharma raised a total of $116.02M.

  • Who are the investors of Athira Pharma?

    Investors of Athira Pharma include Suzanne Kayne, Perceptive Advisors, Rock Springs Capital, Sofinnova Ventures, Avidity Partners and 23 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.